Research Projects & Grants

For Profit Organization

  • A PHASE 3, MULTI-CENTER, RANDOMIZED, PARALLEL, DOUBLE MASKED, PLACEBO-CONTROLLED CLINICAL STUDY TO ASSESS THE SAFTERY AND EFFICACY OF 0.1 % RGN-259 OPHTHALMIC SOLUTION FOR THE TREATMENT OF NEUROTROPHIC KERATOPATHY (SEER-2), Role: PI, ReGen Tree, LLC, (08/2023 - 08/2024) Status: Approved
  • Study to Evaluate the Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants with Persistent Corneal Epithelial Defect (PCED), Role: PI, Combangio, Inc., (05/2023 - 05/2024) Status: Approved
  • CSB-C20-003: A Multi-Center. Randomized, Double-Masked, Vehicle-Controlled. Parallel-Group. Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1 % in stage 2 and 3 Neurotrophic Keratitis Subjects, Role: PI, Claris Biotherapeutics, (11/2023 - 11/2024) Status: Approved

Internal

  • Retrospective Analysis of Incidence, Prevalence, and Treatment Modalities of Neurotrophic Keratitis Post-Retinal Procedures, Role: Investigator, LLU Dept. of Ophthalmology, (08/2023) Status: Approved
  • The effects of call on dry eye symptoms as measured by the Schirmer Test, Role: PI, LLU Dept. of Ophthalmology, (07/2013 - 07/2014) Status: Completed